REPRODUCTIVE HEALTH DRUGS ADVISORY COMMITTEE

April 10, 2000

Uprimal

Slides

TAP Holdings Inc.

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

General Introduction, James Freston, MD, PhD .ppt .html

Apomorphine Pharmacokinetics and Metabolism, Barbara Bopp, PhD .ppt .html

ED Treatments, Jeremy Heaton, MD .ppt .html

Summary of Efficacy, Jeremy Heaton, MD .ppt .html

Summary of Safety

James Freston, MD, PhD .ppt .html

Timothy Fagan MD .ppt .html

Benefit-Risk Assessment/Summary, James Freston, MD, PhD .ppt .html

FOOD AND DRUG ADMINSTRATION

Overview, Daniel A Shames, PhD .pdf

Pharmacokinetics and Drug-Alcohol Interactions, Venkateswar Jarugula, PhD .pdf

Clinical Safety and Efficacy, Mark Hirsch, MD .pdf

Drug-Antihypertensive Interactions, Marianne Mann, MD .pdf